Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions.
Barberi-Heyob
M
M
Merlin
J L
JL
Vigneron
M
M
Conroy
T
T
D002277:Carcinoma / Q000188:drug therapy / Q000401:mortality / Q000556:secondary; D002406:Catheterization, Peripheral; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D004355:Drug Stability; D005472:Fluorouracil / Q000008:administration & dosage*; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D007262:Infusions, Intravenous / Q000295:instrumentation; D008113:Liver Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary; D011169:Portal Vein; D016032:Randomized Controlled Trials as Topic; D013927:Thrombosis / Q000517:prevention & control*
D006493:Heparin; D005472:Fluorouracil